NCT03159702View on ClinicalTrials.gov

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

November 12, 2024

Study Completion Date

November 15, 2025

Conditions
Hematological MalignancyMultiple Myeloma
Interventions
DRUG

Evomela

140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3

DRUG

Fludarabine

40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2

RADIATION

Total Body Irradiation

200 cGy on Day: -1

Trial Locations (1)

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER